Kangjie Medical Announces 2021 Net Profit Forecast of RMB 16–18 Million, Up 58%–78% YoY, Driven by Higher Sales of High-Value-Added Products

This article is sourced from: Wabei.com

Wabei.com, December 27th — Kangjie Medical (430521) recently released its 2021 annual earnings forecast, expecting a year-over-year increase in performance. The net profit attributable to the shareholders of the listed company during the reporting period is expected to be RMB 16 million–18 million, representing a growth of 58.06%-77.82% compared to the same period last year.

The main reasons for the year-on-year growth in performance during this reporting period are: the company has increased the production of new products and raised the proportion of production and sales of high value-added products, leading to an increase in gross margin; the company has digitally upgraded its basic products to meet the needs of the downstream market and customers, and the competitive ability and profitability of the company's products have continued to improve.

Digibao's research shows that Kangjie Medical is a high-tech enterprise engaged in the field of optometry and ophthalmology, integrating R&D, production, and sales. Its main products include slit lamp microscopes, slit lamp image processing systems, direct ophthalmoscopes, streak retinoscopes, fundus cameras, corneal topographers, and tonometers.